1
|
Kim KM, Lee KG, Lee S, Hong BK, Yun H, Park YJ, Yoo SA, Kim WU. The acute phase reactant orosomucoid-2 directly promotes rheumatoid inflammation. Exp Mol Med 2024; 56:890-903. [PMID: 38556552 PMCID: PMC11058272 DOI: 10.1038/s12276-024-01188-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2023] [Revised: 12/04/2023] [Accepted: 12/20/2023] [Indexed: 04/02/2024] Open
Abstract
Acute phase proteins involved in chronic inflammatory diseases have not been systematically analyzed. Here, global proteome profiling of serum and urine revealed that orosomucoid-2 (ORM2), an acute phase reactant, was differentially expressed in rheumatoid arthritis (RA) patients and showed the highest fold change. Therefore, we questioned the extent to which ORM2, which is produced mainly in the liver, actively participates in rheumatoid inflammation. Surprisingly, ORM2 expression was upregulated in the synovial fluids and synovial membranes of RA patients. The major cell types producing ORM2 were synovial macrophages and fibroblast-like synoviocytes (FLSs) from RA patients. Recombinant ORM2 robustly increased IL-6, TNF-α, CXCL8 (IL-8), and CCL2 production by RA macrophages and FLSs via the NF-κB and p38 MAPK pathways. Interestingly, glycophorin C, a membrane protein for determining erythrocyte shape, was the receptor for ORM2. Intra-articular injection of ORM2 increased the severity of arthritis in mice and accelerated the infiltration of macrophages into the affected joints. Moreover, circulating ORM2 levels correlated with RA activity and radiographic progression. In conclusion, the acute phase protein ORM2 can directly increase the production of proinflammatory mediators and promote chronic arthritis in mice, suggesting that ORM2 could be a new therapeutic target for RA.
Collapse
Affiliation(s)
- Ki-Myo Kim
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea
- Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Kang-Gu Lee
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea
- Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Saseong Lee
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea
| | - Bong-Ki Hong
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea
| | - Heejae Yun
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea
- Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea
| | - Yune-Jung Park
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea
- Division of Rheumatology, Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea
| | - Seung-Ah Yoo
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea.
- Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
| | - Wan-Uk Kim
- Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul, South Korea.
- Department of Internal Medicine, The Catholic University of Korea, Seoul, South Korea.
| |
Collapse
|
2
|
Ohto H, Denomme GA, Ito S, Ishida A, Nollet KE, Yasuda H. Three non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jr a cases. Transfus Apher Sci 2020; 59:102949. [PMID: 32994126 DOI: 10.1016/j.transci.2020.102949] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Maternal alloantibody-mediated hemolytic disease of the fetus and newborn (HDFN) ranges from no or mild symptoms to severe hydrops and intrauterine fetal demise. Hemolytic anti-D-mediated HDFN proceeds via a long-known mechanism, to which three other pathways to fetal/neonatal anemia may be added: (0) Fetal erythrocyte destruction can proceed by extravascular phagocytosis. (1) An apoptotic pathway has been described for anti-Kell, and anti-Ge3. (2) Erythropoietic suppression may arise from altered or deformed erythroblast architecture in anti-M-mediated disease. (3) Clonal escape from erythropoietic suppression is hypothesized to arise from maternal anti-Jra immune pressure, albeit this requires further elucidation. Alloantibody-mediated anemic disease of the fetus and newborn (ADFN) is a designation we favor for cases when hemolysis or hyperbilirubinemia are not the dominant features, such as those provoked by anti-Kell, anti-Ge3, anti-M, and anti-Jra.
Collapse
Affiliation(s)
- Hitoshi Ohto
- Fukushima Medical University, Fukushima, 960-1295, Japan.
| | - Gregory A Denomme
- Blood Research Institute / Diagnostic Laboratories, Versiti, Milwaukee, WI, USA
| | - Shoichi Ito
- Japanese Red Cross Tohoku Block Blood Center, Sendai, Japan
| | - Atsushi Ishida
- Department of Pediatrics, Gifu Prefectural Tajimi Hospital, Gifu, Japan
| | - Kenneth E Nollet
- Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
| | | |
Collapse
|
3
|
Gourri E, Denomme GA, Merki Y, Scharberg EA, Vrignaud C, Frey BM, Peyrard T, Gassner C. Genetic background of the rare Yus and Gerbich blood group phenotypes: homologous regions of theGYPCgene contribute to deletion alleles. Br J Haematol 2017; 177:630-640. [DOI: 10.1111/bjh.14578] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 12/11/2016] [Indexed: 01/13/2023]
Affiliation(s)
- Elise Gourri
- Department of Molecular Diagnostics and Research & Development; Blood Transfusion Service Zürich; Swiss Red Cross (SRC); Zürich-Schlieren Switzerland
| | - Gregory A. Denomme
- Diagnostic Laboratories and Blood Research Institute; Blood Center of Wisconsin; Milwaukee WI USA
| | - Yvonne Merki
- Department of Molecular Diagnostics and Research & Development; Blood Transfusion Service Zürich; Swiss Red Cross (SRC); Zürich-Schlieren Switzerland
| | - Erwin A. Scharberg
- Institute of Transfusion Medicine and Immunohematology, Baden-Baden; German Red Cross Blood Service Baden-Württemberg - Hessen; Baden-Baden Germany
| | - Cedric Vrignaud
- Département Centre National de Référence pour les Groupes Sanguins; Institut National de la Transfusion Sanguine (INTS); Paris France
- Inserm UMR_S1134; Paris France
- Laboratoire d'Excellence GR-Ex; Paris France
| | - Beat M. Frey
- Department of Molecular Diagnostics and Research & Development; Blood Transfusion Service Zürich; Swiss Red Cross (SRC); Zürich-Schlieren Switzerland
| | - Thierry Peyrard
- Département Centre National de Référence pour les Groupes Sanguins; Institut National de la Transfusion Sanguine (INTS); Paris France
- Inserm UMR_S1134; Paris France
- Laboratoire d'Excellence GR-Ex; Paris France
| | - Christoph Gassner
- Department of Molecular Diagnostics and Research & Development; Blood Transfusion Service Zürich; Swiss Red Cross (SRC); Zürich-Schlieren Switzerland
| |
Collapse
|
4
|
Wang D, Seto E, Shu J, Micieli JA, Fernandes BJ, Denomme GA. Antibody-mediated glycophorin C coligation on K562 cells induces phosphatidylserine exposure and cell death in an atypical apoptotic process. Transfusion 2013; 53:2134-40. [PMID: 23278312 DOI: 10.1111/trf.12028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2012] [Revised: 09/26/2012] [Accepted: 10/31/2012] [Indexed: 11/30/2022]
Abstract
BACKGROUND Glycophorin C (GPC) is necessary in the maintenance of red blood cell structure. Severe autoimmune hemolytic anemia and hemolytic disease of the fetus and newborn (HDFN) have been associated with Gerbich (Ge) blood group system antigens expressed on GPC. Previous in vitro studies with cord blood progenitor cells have shown that anti-Ge suppresses erythropoiesis. STUDY DESIGN AND METHODS Here, we evaluated the K562 erythroleukemic cell line to study the cellular effects of a murine anti-GPC. Cell proliferation was evaluated after treatment with anti-GPC. Flow cytometry was used to evaluate exofacial phosphatidylserine (PS) expression and cell viability (propidium iodide binding). Cell morphology was evaluated under light microscopy with cytospin preparations stained with May-Grünwald Giemsa. RESULTS Anti-GPC dramatically inhibited K562 proliferation and increased PS expression, consistent with cytoplasmic blebbing, suggesting evidence of apoptosis. Z-VAD-FMK, an inhibitor of classical apoptosis, was unable to reverse the suppressive effect of anti-GPC. However, hemin was able to attenuate growth suppression. CONCLUSION Together, the data suggest that anti-GPC suppresses erythroid proliferation through the induction of nonclassical apoptosis.
Collapse
Affiliation(s)
- Duncheng Wang
- Immunohematology Reference Laboratory, BloodCenter of Wisconsin, Milwaukee, Wisconsin; Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada; Research & Development, Canadian Blood Services, Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
5
|
Pate LL, Myers JC, Palma JP, Viele M, Galel SA, Ferrer Z, Gonzalez CL, Benitz WE, Garratty G, Fontaine MJ. Anti-Ge3 causes late-onset hemolytic disease of the newborn: the fourth case in three Hispanic families. Transfusion 2012; 53:2152-7. [PMID: 23241141 DOI: 10.1111/trf.12027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Revised: 10/26/2012] [Accepted: 10/30/2012] [Indexed: 11/30/2022]
Abstract
BACKGROUND The Gerbich (Ge) blood group system consists of 11 antigens carried on red blood cell (RBC) membrane glycophorins C and D; of these, Ge:3 antigen is of high prevalence, and the anti-Ge3 is found to be clinically significant. CASE REPORT A 34-week neonate born to a Hispanic mother with anti-Ge3 developed late-onset hemolysis with hyperbilirubinemia and was successfully treated with transfusions from her mother. Relevant clinical findings and laboratory results for this case are summarized and compared to three other previously reported cases; all babies were born from a mother of Hispanic ethnicity. CONCLUSION Hemolytic disease of the fetus and new born associated with anti-Ge3 is rare but should be considered when working up a broadly reactive RBC antibody screen in women of Hispanic ethnicity. Early identification of pregnant women with anti-Ge3 is recommended for prenatal transfusion planning and close monitoring of the newborn infant for evidence of late-onset anemia.
Collapse
Affiliation(s)
- Lisa Lee Pate
- Department of Pathology, Stanford University Medical Center, and the Division of Neonatal and Developmental Medicine, Lucile Packard Children's Hospital, Stanford University, Stanford, California; American Red Cross Blood Services (Southern California Region), Pomona, California
| | | | | | | | | | | | | | | | | | | |
Collapse
|